The 20 best-performing new drugs in the market in 2020

Author: cockle

When it comes to the best-performing new drug in the market in 2020, Veklury (Remdesivir) may be one of the most uncompromising.

Eli Lilly’s neutralizing antibody bamlanivimab has also received emergency use authorization from the FDA, and achieved sales revenue of US$871 million in 2020.

The 20 best-performing new drugs in the market in 2020 (US$100 million)

Source: Company's financial report, Medical Rubik's Cube

In addition to new crown-related drugs, there will also be other drugs that have been on the market soon but have impressive market performance in 2020, including several newly marketed antibody-conjugate drugs.

Blenrep(belantamab mafodotin, GSK)

Blenrep was approved by the FDA and EMA successively in August 2020 for multiple myeloma patients who have received more than 4 therapies.

Tukysa (Tocatinib, Seagen)

Tukysa is an oral TKI inhibitor targeting HER2 protein.

Enhertu (DS-8201, AstraZeneca)

Enhertu is an antibody-conjugated drug targeting HER2.

Padcev (enfortumab vedotin, Seagen)

Padcev is an antibody-conjugated drug composed of anti-Nectin-4 monoclonal antibody and microtubule disrupting agent MMAE.

Reblozyl (Rotsipp, BMS)

Reblozyl was first listed in the United States in November 2019, and achieved sales of $274 million in 2020.

Piqray (alpelisib, Novartis)

Piqray was approved by the FDA in May 2019, with sales of 320 million U.

Dovato (dotegravir + lamivudine, GSK)

Dovato is a two-in-one compound tablet that is taken orally once a day and consists of a fixed dose of dotegravir and lamivudine.

Calquence (Acatinib, AstraZeneca)

Calquence is the second approved BTK inhibitor after Ibrutinib.

Rinvoq (upadacitinib, AbbVie)

AbbVie's oral JAK1 inhibitor Rinvoq was first approved by the FDA in August 2019, and its global sales in 2020 will reach US$731 million.

Erleada (apatamide, Johnson & Johnson)

Erleada was first approved by the FDA in February 2018 and reached sales of US$760 million (+128.

Mvasi (bevacizumab, Amgen)

Mvasi (bevacizumab) is a biosimilar of Roche Avastin, which was temporarily approved by the FDA in September 2017.

Tepezza (teprotumumab, Horizon)

Tepezza is a monoclonal antibody that targets IGF-1R.

Zolgensma (Novartis)

Novartis’ Zolgensma is the first gene therapy to treat SMA.

Ultomiris (ravulizumab, Alexion)

Ultomiris is the first and only long-acting C5 inhibitor.
It is injected every 8 weeks for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults.
It was first approved on December 11, 2018 and sold globally in 2020.
The amount reached 1.
077 billion US dollars (+217.
7%).
Compared with Alexion's previously approved PNH standard therapy with Soliris (eculizumab) once every 2 weeks, Ultomiris prolongs the dosing interval by 4 times, and has the same efficacy and safety.
In addition, Ultomiris is also approved for the treatment of atypical hemolytic uremic syndrome in patients 1 month and older.
In December 2020, AstraZeneca acquired Alexion for a total of 39 billion U.
S.
dollars, and acquired Ultramiris.

Skyrizi (risankizumab, AbbVie)

AbbVie IL-23 monoclonal antibody Skyrizi has been approved in Japan, the European Union, and the United States in March 2019.
It has been approved for 4 indications in more than one year, which are used to treat plaque psoriasis and psoriasis.
For arthritis, generalized pustular psoriasis, and erythroderma-type psoriasis, sales in 2020 will nearly quadruple to reach 1.
59 billion US dollars (+347.
9%).
risankizumab has been shown to be superior to Johnson & Johnson's uzumumab, adalimumab, and skukuzumab in a phase III clinical study for the treatment of moderate to severe plaque psoriasis.
It is a blockbuster product in the field of AbbVie's immunity.
risankizumab is currently in Phase III clinical research in China.

Hemlibra (Eimexizumab, Roche)

Hemlibra jointly developed by Roche/Chugai is a recombinant humanized IgG4 bispecific antibody that bridges coagulation factor IXa and coagulation factor X, mimicking coagulation factor VIIIa in vivo to restore the coagulation function of patients with hemophilia A.
It is the first new drug approved by the FDA for the treatment of hemophilia A (about 1/3) containing factor VIII inhibitors in the body in the past 20 years.
It is also the first bispecific antibody drug approved for marketing in my country.
Compared with the current three times a week intravenous injection of coagulation factor therapy, iimerizumab only needs to be injected subcutaneously once a week, which greatly reduces the burden of injection.
After being first approved in the United States in November 2017, it was only one year later as a clinically urgently needed new drug to accelerate the approval of the NMPA for marketing.
The sales of iimerizumab in 2020 were 2.
19 billion Swiss francs (2.
334 billion US dollars, +58.
7%).

Ozempic (Smegaglutide, Novo Nordisk)

Novo Nordisk's long-acting GLP-1R agonist Ozempic was first approved for marketing in the United States in December 2017 for the treatment of type 2 diabetes.
In January 2020, a new indication for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease was approved.
In 2020, Ozempic's global sales increased by 88.
8% compared with 2019, reaching 21.
211 billion Danish kroner (3.
25 billion US dollars, +110.
3%).
In 2010, it is expected to surpass Eli Lilly's Trulicity (dulaglutide) as the world's best-selling GLP-1 drug.

Dupixent (Duplizumab, Sanofi)

Dupixent is Sanofi’s highest sales product in 2020, reaching 3.
534 billion euros (4.
033 billion US dollars, +70.
4%) in the fourth year of launch, which is expected to fulfill Sanofi’s expectations of its peak sales of 10 billion + euros .
Duplizumab has been approved for 3 indications since it was approved in March 2017, including atopic dermatitis (over 6 years old), asthma, and chronic rhinosinusitis with nasal polyps.
It is the first to be approved The drug used to treat chronic rhinosinusitis with nasal polyps that is not fully controlled is the only biological product approved for oral glucocorticoid-dependent asthma (no phenotype), and the only patient who can Anti-asthma biologics that you inject yourself at home.
Dupixent was approved for the treatment of moderate to severe atopic dermatitis in China in June 2020, and was included in the new medical insurance list at the end of the year.

Biktarvy (Biktarvy, Gilead)

Gilead's new three-in-one compound drug Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide, BIC/FTC/TAF) only needs to be taken orally once a day, with excellent safety and convenience, 2018 It was first approved for marketing in February, and it became the world's most prescribed anti-AIDS drug in less than two years.
Sales in 2020 reached 7.
259 billion U.
S.
dollars (+52.
3%), setting a new single-drug sales record for AIDS drugs.
Biktarvy was approved for listing in China in August 2019.